Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss

 

 

Overview

Corporate Profile

Auris Medical is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of oligonucleotides for extrahepatic therapeutic targets (OligoPhoreTM platform; preclinical), nasal sprays for protection against airborne viruses and allergens (BentrioTM; pre-commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Stock Quote

View more

Latest Press Releases

Read more

Upcoming Events

Various statements that Auris Medical Holding makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.

In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.

Investors